Does Rallies show 13F holders for EXEL?

Yes. Rallies tracks hedge fund and 13F ownership data for EXEL, including fund names, share counts, latest tracked quarter, and position changes when available.

Is EXEL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for EXEL. It does not provide personalized investment advice.

EXEL (Exelixis) Stock Analysis - Hedge Fund Holdings

Exelixis (EXEL) is a publicly traded Healthcare sector company. As of May 21, 2026, EXEL trades at $49.31 with a market cap of $12.53B and a P/E ratio of 27.62. EXEL moved +2.56% today. Year to date, EXEL is +17.69%; over the trailing twelve months it is +12.49%. Its 52-week range spans $25.17 to $51.63. Analyst consensus is buy with an average price target of $47.70. Rallies surfaces EXEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns EXEL stock?

Hedge funds tracked by Rallies that own EXEL include Farallon Capital, Bridgewater Associates, Pinebridge Investments, Eisler Capital, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Exelixis.

EXEL Key Metrics

Key financial metrics for EXEL
Metric	Value
Price	$49.31
Market Cap	$12.53B
P/E Ratio	27.62
EPS	$1.80
Dividend Yield	0.00%
52-Week High	$51.63
52-Week Low	$25.17
Volume	1.84M
Avg Volume	0
Revenue (TTM)	$2.17B
Net Income	$521.27M
Gross Margin	96.49%

Top Hedge Funds Holding EXEL

Farallon Capital holds 13.11M shares of EXEL, changed -16.54% as of Mar 31, 2026.
Bridgewater Associates holds 481.00K shares of EXEL, changed -48.04% as of Mar 31, 2026.
Pinebridge Investments holds 66.04K shares of EXEL, changed -9.32% as of Sep 30, 2025.
Eisler Capital holds 36.56K shares of EXEL, changed +21.82% as of Jun 30, 2024.
Panagora Asset holds 6.64K shares of EXEL, changed -86.41% as of Mar 31, 2026.

Latest EXEL News

Exelixis jumps as Q1 EPS beats, $750M new buyback adds support — May 6, 2026
Exelixis slides as RBC trims target to $43 ahead of early-May earnings focus — Apr 24, 2026
Exelixis climbs as pipeline catalysts and 2026 outlook refocus attention on growth — Apr 22, 2026
Exelixis climbs as Barclays lifts price target to $45 ahead of May earnings — Apr 21, 2026
Exelixis slips as insider-sale headlines resurface ahead of May earnings — Apr 15, 2026

Recent EXEL Insider Trades

Senner Christopher J. sold 34.90K (~$1.75M) on May 18, 2026.
Hefti Brenda sold 6.63K (~$332.64K) on May 18, 2026.
Beckerle Mary C sold 7.71K (~$373.65K) on May 7, 2026.

EXEL Analyst Consensus

11 analysts cover EXEL: 0 strong buy, 5 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $47.70.

Common questions about EXEL

Who owns EXEL stock?: Hedge funds tracked by Rallies that own EXEL include Farallon Capital, Bridgewater Associates, Pinebridge Investments, Eisler Capital, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Exelixis.
Does Rallies show 13F holders for EXEL?: Yes. Rallies tracks hedge fund and 13F ownership data for EXEL, including fund names, share counts, latest tracked quarter, and position changes when available.
Is EXEL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for EXEL. It does not provide personalized investment advice.